澳优 (1717 HK) 25 年国内业务承压但海外市场亮眼 2026 年 2 月 03 日│中国香港 食品 我们预计公司 2025 年收入 74.8 亿元，同比+1.1%，净利润 2.4 亿元，同比 +1.3%，对应 25H2 收入预计同比-3.4%，净利润预计同比-35.4%。据国家 统计局，25 年中国新生人口数量为 792 万人，同比净减少 162 万人，对国 内婴配粉行业的需求形成压力；据尼尔森，25 年国内婴配粉行业销售额小 幅下滑，其中销量同比小幅下滑。我们预计公司 25H2 国内的羊奶粉与牛奶 粉 BU 的收入均未恢复增长，但海外业务预计延续了较好的收入成长，主因 集团对于海外团队的激励机制进行梳理，海外团队的积极性进一步提升，国 内的成熟打法（如会员模式等）在海外市场效果显著；叠加海外市场竞争压 力相对较小，且公司拥有美国 FDA 配方批文、荷兰奶源等差异化优势等。 利润端，行业竞争加剧对 25H2 利润形成拖累，期待后续改善。维持"增持"。 收入端：25 年国内业务有所拖累，海外业务延续较好的收入成长 据国家统计局，25 年中国新生人口数量为 792 万人，同比净减少 162 万人， 对国 ...

Group 1 - The company is expected to see a revenue growth of 1.1% year-on-year in 2025, with a slowdown in growth primarily due to the domestic milk powder business [1] - The company's net profit attributable to shareholders is projected to remain flat year-on-year in 2025, with a decline in profit in the second half of 2025 mainly due to slower internal code transition and intensified industry competition [1] - Factors affecting the company's performance include a delayed internal code switch, increased competition with other companies offering subsidies or price cuts, and a slowdown in industry revenue growth [1] Group 2 - The completion of the internal code switch in December 2025 and the resolution of channel inventory issues are expected to lead to improvements in domestic business revenue in 2026 [2] - The overseas business is identified as a key growth driver, with stable contributions from markets like the Middle East and Saudi Arabia, and plans to expand into Southeast Asia and North America [2] - The company's net profit forecasts for 2025-2027 have been revised down to 236 million, 262 million, and 280 million yuan respectively, reflecting pressures from declining birth rates and increased competition [2]

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 1）低基数+内码切换完成：25年12月内码切换完成、渠道库存理顺后出现改善迹象（12月公司羊奶粉及 牛奶粉市场份额均实现同比增长；一段产品会员数环比增长），以及25年业绩低基数，26年公司国内业务 收入有望温和改善。2）海外业务顺利推进：海外业务是公司重要增长引擎，中东（贡献海外近半业 绩）、沙特（潜在空间最大市场）等市场稳定；25年下半年拓展的东南亚市场，由专人统筹且聚焦高端客 群，其中印度市场25年启动前期工作，预计27年正式推出产品；北美市场更换团队后逐步起量。渠道方 面，佳贝艾特已成功进入海外医药渠道，覆盖传统商超、电商等多元场景；研发端同步开展当地医药研 发，进一步强化海外业务竞争力。26年公司海外业务收入有望维持快速增长。 ...

2026 年 2 月 2 日 公司研究 因内码调整进度偏慢拖累，预计 25H2 业绩承压 ——澳优（1717.HK）2025 年业绩前瞻 资料来源：Wind，光大证券研究所预测，股价时间为 2026-01-30 （注：汇率为 1 港币=0.8926 元人民币，23-27 年股本 数分别为 17.80/17.80/17.78/17.78/17.78 亿股） 要点 2025 年业绩前瞻：1）我们预计公司 25 年收入同比增长 1.1%，收入增速较 25H1 放缓主要受国内奶粉业务拖累。2）我们预计公司 25 年归母净利润同比基本持 平；25H2 利润同比下滑主要系内码调整进度低于预期，以及行业竞争加剧，导 致高毛利率的国内奶粉业务收入占比下降。 内部调整滞后、外部行业环境恶化等因素影响，25 年业绩预计不及预期。 1）内码切换进度滞后：25 年 4 月公司启动内码切换工作并同步涨价，消费者提 前囤货，使得内码切换完成时间从三季度延迟至四季度，打乱了下半年核心业务 的增长节奏。2）行业竞争加剧：25 年行业内多家企业推出补贴或降价策略，而 公司此时处于涨价阶段，在价格竞争中处于被动地位。3）行业收入增速下滑： 25 ...

Core Viewpoint - Guotou Securities International has downgraded Ausnutria (01717) to a "Buy" rating due to anticipated challenges in the domestic milk powder industry and a significant decline in birth rates projected for 2025 [1][7]. Group 1: Birth Rate Decline - The birth population for 2025 is projected to be 79.2 million, a 17% decrease year-on-year, with a birth rate of 5.63‰ [2][7]. - In 2024, being the Year of the Dragon, there is an expected slight increase in birth rates, reaching 9.54 million, leading to a temporary easing of competition in the milk powder industry in the first half of 2025 [2][7]. Group 2: Company Performance - Ausnutria reported total revenue of 3.89 billion yuan in the first half of the year, a year-on-year increase of 5.6%, and a net profit of 181 million yuan, up 21.4% [8]. - The growth was primarily supported by overseas goat milk powder, which generated 1.86 billion yuan in revenue, a 3.1% increase year-on-year, with overseas sales reaching 480 million yuan, a 65.7% increase, accounting for 26% of goat milk powder revenue [8]. - Domestic goat milk powder revenue was 1.38 billion yuan, down 8.9%, and cow milk powder revenue was 960 million yuan, down 14.9%, attributed to a system upgrade and inventory adjustments that reduced short-term shipments [8]. Group 3: Profitability and Margin Pressure - The gross margin for the first half of 2025 was 41.9%, a decrease of 1.5 percentage points year-on-year [9]. - The gross margin for goat milk powder decreased by 0.8 percentage points to 55.1%, while cow milk powder's gross margin also fell by 0.8 percentage points to 52.3% [9]. - The introduction of internal code products has slightly pressured the gross margins, and further downward pressure on margins is expected in the second half of the year [9].

产品结构拉低毛利率 智通财经APP获悉，国投证券国际发布研报称，下调澳优(01717)至"增持"评级。2025年出生人口为792 亿，同比下降17%，出生率为5.63‰，考虑国内奶粉行业竞争仍然激烈，并且明年还有竞争加剧的可 能，该行预期下半年公司的业务仍将承压，该行下调25/26/27年净利润至2.5/2.6/2.9亿元，对应每EPS收 益为0.16/0.16/0.18港元，下调目标价至2.3港元，较当前股价有9%的涨幅。 国投国际证券主要观点如下： 2025年出生人口大幅下滑 2025年出生人口为792亿，同比下降17%，出生率为5.63‰。2024年为龙年，因此出生人口出现了小幅 攀升，达到954万，因此在25年上半年奶粉行业出现了一定程度的竞争缓和。到25年下半年，随着出生 人口的影响逐渐显现，行业将继续面临较为激烈的竞争，并且有望持续到明年。 澳优上半年业绩实现增长 上半年实现总营业收入38.9亿元，同比增长5.6%;实现净利润1.81亿元，同比增长21.4%。其中海外羊奶 粉支撑增长，25年上半年羊奶粉收入18.6亿元，同比增长3.1%。其中海外羊奶粉收入4.8亿，同比增长 65.7%，占羊奶粉收 ...

Investment Rating - The investment rating for the company is downgraded to "Buy" with a target price of HKD 2.3, representing a potential upside of 9% from the current stock price of HKD 2.08 [1][6]. Core Insights - The domestic milk powder business continues to face pressure due to a significant decline in the birth rate, with the 2025 birth population projected at 79.2 million, a 17% year-on-year decrease [1][2]. - The company reported a revenue of RMB 3.89 billion for the first half of 2025, a 5.6% increase year-on-year, and a net profit of RMB 181 million, up 21.4% year-on-year, driven by overseas goat milk powder sales [2][3]. - The gross margin for the first half of 2025 was 41.9%, down 1.5 percentage points year-on-year, with goat milk powder and cow milk powder margins also declining [3]. Financial Summary - Revenue projections for 2025, 2026, and 2027 are adjusted to RMB 2.5 billion, RMB 2.6 billion, and RMB 2.9 billion respectively, with corresponding EPS estimates of HKD 0.16, HKD 0.16, and HKD 0.18 [1][4]. - The company’s financial performance shows a decline in domestic goat milk powder revenue by 8.9% and cow milk powder revenue by 14.9% in the first half of 2025 [2][3]. - The average P/E ratio for comparable companies is estimated at 11.7x, with the company assigned a P/E of 13x due to its overseas business development [12]. Valuation Analysis - The DCF valuation method estimates a reasonable market value of HKD 2.4 based on a WACC of 7.2% and a short-term growth rate of 4% [12]. - The target price of HKD 2.3 is derived from a combination of comparable company analysis and DCF valuation, indicating a potential upside from the current market price [12].

Core Viewpoint - The competition in China's infant formula market is intensifying, with both Yili and Feihe claiming the top position based on different metrics [2][3][4]. Company Performance - Yili has achieved the highest market share in the overall infant formula market, including both cow and goat milk formulas, with a market share of 18.1%, an increase of 1.3 percentage points year-on-year [3]. - Yili's revenue from milk powder and dairy products grew by 14.26% year-on-year to 16.578 billion yuan, with infant formula sales experiencing double-digit growth [3]. - Feihe, on the other hand, reported a revenue decline of 9.36% to 9.151 billion yuan in the same period, despite maintaining its position as the leading single brand in the market [4][7]. Market Dynamics - The difference in rankings arises from the fact that Yili's figures include sales from Aoyou Dairy, which it acquired in 2022, while Feihe's data reflects its standalone brand performance [4][6]. - Aoyou Dairy's performance has not significantly bolstered Yili's sales, as its core goat milk brand, Jiabei Aite, saw a sales decline of 8.9% to 1.38 billion yuan [5][6]. - The market share gap between Yili and Feihe is narrow, with Euromonitor data indicating Feihe's market share at 17.5% and Yili at 16.3% for 2024 [7]. Future Outlook - The infant formula market in China may face contraction due to a significant decline in marriage registrations, which is likely to lead to a decrease in newborn numbers [8]. - However, the market is not deemed unprofitable, as government childcare subsidies may lead to a potential increase in birth rates, and parents are increasingly willing to spend on high-quality products [9]. - The domestic infant formula market is characterized as a key battleground for consumer upgrades, indicating substantial profit potential [10].

Core Viewpoint - The company achieved a revenue of 3.887 billion yuan in H1 2025, representing a year-on-year increase of 5.6%, and a net profit attributable to shareholders of 181 million yuan, up 24.1% year-on-year [1] Group 1: Revenue Breakdown - The company's revenue from milk powder, domestic goat milk powder, and nutritional products in H1 2025 was 961 million, 1.381 billion, and 156 million yuan respectively, with year-on-year changes of -14.9%, -8.9%, and +7.0% [1] - The newly added cheese business generated a revenue of 479 million yuan in H1 2025 [1] - The decline in revenue from milk powder and domestic goat milk powder was primarily due to the launch of an internal code system upgrade in Q2, which led to a temporary reduction in shipment volumes [1] Group 2: Market Performance - The market share of the goat milk powder brand increased to 30.4% by the end of H1 2025, up 2.8 percentage points year-on-year [1] - Overseas revenue from goat milk powder saw a significant increase of 65.7% to 483 million yuan, accounting for 25.9% of the overall goat milk powder business revenue [1] - Key regions such as the Middle East, North America, and the CIS experienced revenue growth of 54.2%, 138.7%, and 33.8% respectively [1] Group 3: Profitability and Cost Management - The gross profit margin for H1 2025 was 41.9%, a decrease of 1.5 percentage points year-on-year, mainly due to the lower gross margin of the newly merged goat cheese business at 6.8% [2] - The sales expense ratio was 26.1%, down 3.8 percentage points year-on-year, attributed to reduced promotional expenses from optimizing channel strategies [2] - The net profit margin attributable to shareholders increased to 4.6%, up 0.7 percentage points year-on-year [2] Group 4: Future Outlook - Despite challenges such as declining birth rates and macroeconomic uncertainties, domestic goat milk powder revenue is expected to improve in H2 2025 as inventory adjustments are completed [3] - The overseas goat milk powder business remains a key growth driver, with the company achieving leading sales on Amazon in the U.S. for goat milk infant formula [3] - The nutritional products segment is being developed as a second growth avenue, focusing on large clients and enhancing online and offline sales channels [3] Group 5: Profit Forecast and Valuation - The company maintains net profit forecasts of 299 million, 357 million, and 410 million yuan for 2025-2027, with corresponding PE ratios of 13x, 11x, and 10x [3] - The company is recognized as a leading brand in goat milk powder with successful overseas market expansion and growth potential [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [6]. Core Insights - The company achieved a revenue of 3.887 billion CNY in H1 2025, representing a year-on-year increase of 5.6%, and a net profit of 181 million CNY, up 24.1% year-on-year [1]. - The overseas goat milk powder segment showed significant growth, with a 65.7% increase in revenue to 483 million CNY, accounting for 25.9% of total goat milk powder revenue [2]. - The company is focusing on optimizing sales expenses and improving net profit margins, with a net profit margin of 4.6% in H1 2025, up 0.7 percentage points year-on-year [3]. - The company anticipates continued strong growth in overseas goat milk powder sales and is developing its nutrition products as a second growth avenue [4]. Summary by Sections Financial Performance - In H1 2025, the company reported revenues of 3.887 billion CNY and a net profit of 181 million CNY, with respective year-on-year growth rates of 5.6% and 24.1% [1]. - The gross profit margin for H1 2025 was 41.9%, a decrease of 1.5 percentage points, primarily due to the lower margin from the newly acquired cheese business [3]. Product Performance - Revenue from cow milk powder, domestic goat milk powder, and nutrition products in H1 2025 was 961 million CNY, 1.381 billion CNY, and 156 million CNY, with year-on-year changes of -14.9%, -8.9%, and +7.0% respectively [2]. - The newly added cheese business generated 479 million CNY in revenue [2]. Market Outlook - The company expects domestic goat milk powder revenue to improve in H2 2025 as inventory adjustments are completed, and policies stimulate demand [4]. - The overseas goat milk powder business remains a key growth driver, with significant sales increases in core regions such as the Middle East and North America [2][4]. Profitability and Valuation - The company forecasts net profits of 299 million CNY, 357 million CNY, and 410 million CNY for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 13x, 11x, and 10x [4].